Damora Therapeutics (DMRA) Share-based Compensation (2020 - 2026)
Damora Therapeutics posted quarterly Share-based Compensation of $8.1 million for Q1 2026, up 4435.2% year-on-year from $179000.0 in Q1 2025, and up 1580.75% on a QoQ basis from $483000.0 in Q4 2025.
Damora Therapeutics (DMRA) has 7 years of Share-based Compensation data on file, last reported at $8.1 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 4435.2% year-over-year to $8.1 million; the trailing twelve-month figure through Mar 2026 stood at $8.9 million (up 334.05% YoY), and the FY2025 full-year result was $998000.0, down 69.19% from the prior year.
- Share-based Compensation for Q1 2026 stood at $8.1 million, up from $483000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $8.1 million in Q1 2026 and bottomed at $164000.0 in Q3 2025.
- The 5-year median for Share-based Compensation is $1.3 million (2022), against an average of $1.4 million.
- The widest annual swing landed in 2025, when Share-based Compensation sank 86.83%; it then soared 4435.2% in 2026.
- A 5-year view of Share-based Compensation shows it stood at $1.3 million in 2022, then retreated by 19.2% to $1.1 million in 2023, then sank by 71.74% to $308000.0 in 2024, then soared by 56.82% to $483000.0 in 2025, then jumped by 1580.75% to $8.1 million in 2026.
- The last three Share-based Compensation figures came in at $8.1 million (Q1 2026), $483000.0 (Q4 2025), and $164000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | 8.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.12 Mn |
| Mar 31, 2026 | 8.12 Mn |
| Dec 31, 2025 | 483,000.00 |
| Dec 31, 2025 | 483,000.00 |
| Sep 30, 2025 | 164,000.00 |
| Sep 30, 2025 | 164,000.00 |
| Jun 30, 2025 | 172,000.00 |
| Jun 30, 2025 | 172,000.00 |
| Mar 31, 2025 | 179,000.00 |
| Mar 31, 2025 | 179,000.00 |
| Dec 31, 2024 | 308,000.00 |
| Dec 31, 2024 | 308,000.00 |
| Sep 30, 2024 | 681,000.00 |
| Sep 30, 2024 | 681,000.00 |
| Jun 30, 2024 | 891,000.00 |
| Jun 30, 2024 | 891,000.00 |
| Mar 31, 2024 | 1.36 Mn |
| Mar 31, 2024 | 1.36 Mn |
| Dec 31, 2023 | 1.09 Mn |
| Dec 31, 2023 | 1.09 Mn |
| Sep 30, 2023 | 1.46 Mn |
| Sep 30, 2023 | 1.46 Mn |
| Jun 30, 2023 | 1.44 Mn |
| Jun 30, 2023 | 1.44 Mn |
| Mar 31, 2023 | 1.43 Mn |
| Mar 31, 2023 | 1.43 Mn |
| Dec 31, 2022 | 1.35 Mn |
| Dec 31, 2022 | 1.35 Mn |
| Sep 30, 2022 | 1.40 Mn |
| Sep 30, 2022 | 1.40 Mn |
| Jun 30, 2022 | 1.42 Mn |
| Jun 30, 2022 | 1.42 Mn |
| Mar 31, 2022 | 1.40 Mn |
| Mar 31, 2022 | 1.40 Mn |
| Dec 31, 2021 | 1.24 Mn |
| Dec 31, 2021 | 1.24 Mn |
| Sep 30, 2021 | 1.22 Mn |
| Sep 30, 2021 | 1.22 Mn |
| Jun 30, 2021 | 987,000.00 |
| Jun 30, 2021 | 987,000.00 |
| Mar 31, 2021 | 1.03 Mn |
| Mar 31, 2021 | 1.03 Mn |
| Dec 31, 2020 | 502,000.00 |
| Dec 31, 2020 | 502,000.00 |
| Sep 30, 2020 | 134,000.00 |
| Sep 30, 2020 | 134,000.00 |
| Jun 30, 2020 | 374,000.00 |
| Jun 30, 2020 | 374,000.00 |